解脲支原体感染新生儿的临床特征分析OACSTPCD

Objective To analyze the clinical characteristics of newborns infected with ureaplasma urealyticum,providing a basis for clinical diagnosis and treatment.Methods A retrospective analysis of the clinical data of 94 newborns with ureaplasma urealyticum infection admitted to the department of neonatology of Liuzhou Maternity and Child Health Hospital from June 2019 to June 2021 was conducted.They were divided into preterm and term groups according to their gestational age.The basic information of the mothers,laboratory examination results,and complications of the two groups of patients were compared.And the effectiveness and safety of different macrolide antibiotics in the treatment were evaluated.Results The incidence of respiratory tract ureaplasma urealyticum was 14.95% ,more common in premature infants,especially extremely preterm infants.Premature infants are most commonly associated with premature rupture of membranes,while term infants are most commonly associated with antenatal fever.There was no significant difference in blood routine results between the two groups of patients(P＞0.05).Premature infants are more prone to pathological jaundice,neonatal pneumonia,neonatal respiratory distress syndrome(NRDS),and bronchopulmonary dysplasia(BPD)than term infants(X2=8.002,15.499,12.185 and 5.406,respectively,all P＜0.05).The effective rates of azithromycin and erythromycin for the treatment of preterm infants with ureaplasma urealyticum infection were 81.82% and 75.00% ,respectively.There was no significant difference in the hospitalization time,oxygen therapy time,duration of invasive ventilation,postnatal intubation,necrotizing enterocolitis(NEC),BPD,retinopathy of prematurity(ROP),and conversion rate between different drug treatment groups(t/X2=-0.736,-0.132,1.754,0.509,0.157,0.242,2.070 and 0.001,respectively,all P＞0.05).Conclusion Ureaplasma urealyticum has certain effects on newborns and their mothers,and there is no significant difference in efficacy between azithromycin and erythromycin in the treatment of premature infants with ureaplasma urealyticum infection.